Insulin Delivery Device Companies

The insulin delivery devices market is projected to reach USD 52.7 billion by 2030 from USD 35.3 billion in 2025, at a CAGR of 8.3% from 2025 to 2030.

The insulin delivery devices market is set for significant growth due to the increasing prevalence of type 1 diabetes. Factors such as an aging population and the rise of lifestyle-related diseases are contributing to a growing number of individuals with diabetes, which, in turn, boosts the demand for effective insulin delivery devices, including insulin pens and insulin pumps. Additionally, a rise in healthcare spending on diabetes treatment creates promising opportunities for market expansion. Ongoing research and development and strategic alliances among key market players are driving innovation and growth in this sector. Together, these factors are expected to propel the insulin delivery devices market during the forecast period.

To know about the assumptions considered for the study download the pdf brochure

Some major players in the insulin delivery devices market with a significant global presence include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Medtronic Plc (Ireland), Sanofi (France), and Eli Lilly and Company (US). These companies have employed a variety of growth strategies, both organic and inorganic, including acquisitions, product launches, product approvals, partnerships, and expansions. These strategies have enabled them to strengthen their international footprint and capture a larger market share of insulin delivery devices. As a result, these market players have successfully expanded their reach across different geographies by offering innovative insulin delivery devices.

• In January 2025, Novo Nordisk A/S launched Awiqli (insulin icodec injection) in Japan using a prefilled FlexTouch pen.
• In December 2024, Novo Nordisk A/S (Denmark) acquired three manufacturing facilities from Novo Holdings A/S. This acquisition occurred after Novo Holdings completed its purchase of Catalent, Inc., a prominent global contract development and manufacturing organization (CDMO). The integration of these manufacturing sites supports Novo Nordisk's strategic goal of expanding access to its existing and future treatments for individuals with diabetes and obesity.
• In May 2024, Novo Nordisk A/S (Denmark) received approval from the European Medicines Agency (EMA) for Awiqly (insulin icodec), a once-weekly insulin. The approval includes its presentation in a glass cartridge within a prefilled pen (FlexTouch).
• In May 2023, Embecta Corp (US) partnered with Tidepool (US) to develop an automated insulin delivery (AID) system for type 2 diabetes (T2D). Embecta will leverage Tidepool’s expertise in diabetes management software to design the AID algorithm for its closed-loop patch pump system.

Embecta Corp. (US) was formed after a spin-off from Becton, Dickinson and Company (BD) in April 2022. It offers a variety of insulin delivery devices, including insulin pen needles and syringes, catering to the global insulin delivery devices market. The company operates in more than 100 countries worldwide and is the largest manufacturer of insulin syringes and pen needles. Annually, it produces approximately 6 billion pen needles and 1.5 billion syringes, underscoring its established leadership in injection-based delivery systems.

The company has strengthened its market position in the US by securing exclusive or dual-preferred brand status with three major Medicare Part D payers. The company is committed to innovation and collaboration with key industry partners. For example, in May 2023, it announced a partnership with Tidepool (US) to develop an automated insulin delivery (AID) system for individuals with type 2 diabetes. These initiatives solidify the company's strategic direction to advance medical technology and meet patient needs in the insulin delivery devices market.

Novo Nordisk A/S (Denmark) operates through two primary business segments focused on therapeutic areas: Diabetes and Obesity Care and Rare Disease (formerly Biopharm). Within the Diabetes and Obesity Care segment, Novo Nordisk offers a comprehensive range of products, including various types of insulin, GLP-1 analogs, glucagon, oral antidiabetic medications, obesity treatments, and related delivery devices such as insulin pens and needles. The company also provides innovative diabetes care solutions, including intelligent insulin pens and Dose Check, an insulin dose guidance software. Insulin injection devices are a key part of this segment, enhancing the user experience.

Novo Nordisk has a significant global presence, with offices in 80 countries and products available in more than 170 markets. Its operations span North America, Europe, the Middle East, Latin America, Africa, Oceania, and the Asia Pacific. The company conducts research and development in five countries, operates production facilities in thirteen, and engages in commercial activities across 80 nations worldwide.

Novo Nordisk emphasizes innovation and portfolio optimization to strengthen its foothold in the insulin delivery devices market. It has launched insulin pens such as the NovoPen 6. Furthermore, the acquisition of BIOCORP Production SA (France) in June 2023 enhances Novo Nordisk’s capabilities in connected drug delivery, advancing its focus on integrating smart insulin pens with digital health solutions for diabetes management. With established expertise in large-scale production and device development, the company optimizes its insulin delivery devices continuously.

Market Ranking

The ranking of firms in the insulin delivery devices market is based on market share analysis, secondary research, and validation from primary respondents. This ranking takes into account revenue from the breadth and depth of product portfolios, innovation, and approvals or launches. The insulin delivery devices market is competitive, with five main players collectively holding 25% to 50% of the total market share. The key players identified in the analysis are Embecta Corp. (US), Novo Nordisk A/S (Denmark), Medtronic Plc (Ireland), Sanofi (France), and Eli Lilly and Company (US).

Embecta Corp. is distinguished in the industry for its diverse range of advanced insulin delivery devices. Novo Nordisk A/S has a strong global presence with its advanced portfolio of insulin pens and needles. Medtronic Plc is noted for its significant variety of products worldwide, and the company actively engages in both organic and inorganic strategies to maintain its market position. Sanofi and Eli Lilly stand out for their innovative insulin pens.

The remaining 50% to 75% of the market share is held by various regional and emerging vendors, which contributes to extensive fragmentation and creates opportunities for smaller players to establish a presence in the market.

Related Reports:

Insulin Delivery Device Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (Tethered, Tubeless), Insulin Pen Needle (Standard, Safety), Insulin Syringes, Others), Disease Type (Type 1 Diabetes, Type 2 Diabetes) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com